

# COC Horizon Scanning 2021

## In this guide

### [In this guide](#)

1. [About the Committees](#)
2. [Committee on the Toxicity of Chemicals in Food, Consumer Products and the Environment -Preface 2021](#)
3. [COT Evaluations 2021](#)
4. [Updated COT Evaluations 2021](#)
5. [Committee Procedures](#)
6. [COT Ongoing Work 2021](#)
7. [COT Working Groups 2021](#)
8. [2021 Membership of the Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment](#)
9. [Declaration of COT members interests during the period of this report- 2021](#)
10. [Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment-Preface 2021](#)
11. [COM Ongoing Work 2021](#)
12. [COM Evaluations 2021](#)
13. [COM Horizon Scanning 2021](#)
14. [2021 Membership of the Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment](#)
15. [Declaration of COM members interests during the period of this report 2021](#)
16. [Committee on the Carcinogenicity of Chemicals in Food, Consumer Products and the Environment - Preface 2021](#)
17. [COC Evaluations 2021](#)
18. [COC Joint Ongoing Topics 2021](#)
19. [COC Horizon Scanning 2021](#)
20. [COC Working Groups 2021](#)
21. [COC Guidance Statements 2021](#)
22. [2021 Membership of the Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment](#)
23. [Declaration of COC members interests during the period of this report 2021](#)
24. [Annex 1 - Terms of Reference](#)

25. [Annex 2 - Code of Conduct for members of the COC/COM/COT](#)
26. [Annex 3 - Openness](#)
27. [Annex 4 - Good Practice Agreement for Scientific Advisory Committees](#)
28. [Annex 5 - Glossary of Terms](#)
29. [Annex 7 - Previous Publications](#)

3.21 The COC undertakes horizon scanning exercises at regular intervals with the aim of identifying new and emerging issues which have potential to impact on public health.

3.22 At the end of discussion in 2021, it was agreed that the priority topics were:

- Maintain a watching brief on factors affecting cancer susceptibility including shift work, stress and other lifestyle factors and how that might affect assessment of chemicals and carcinogenicity.
- Consider an update to guidance on assessment of nanomaterials, possibly as a joint activity across COC, COM and COT.
- Gain awareness of the potential effects of antibiotics and antivirals on the microbiome.
- Consider a joint discussion with COM on thresholds for in vivo mutagens and whether there is new information subsequent to the 2010 COM opinion.
- Endocrine disruption and the link with carcinogenicity, acknowledging that endocrine disruption is also within the COT remit.
- Impact of chemicals on potential for metastasis or progression of cancer, in particular with respect to the tumour microenvironment.
- Communication of cancer risk and how COC should be involved with this, especially with the move away from a yes/no decision on whether a substance is a carcinogen, and ensuring consistency in describing risks, possibly starting with a landscape review of terminology across a number of Committees (FSA and UKHSA) and led by Lay Members.
- Ensuring appropriate considerations are made to acknowledging diversity in the population especially where there might be differences in risk between different groups.

3.23 The Committee continues to have a standing agenda item for each meeting on horizon scanning topics and to update the COC on upcoming topics for UK and international scientific advisory groups.